Second Sight Medical Products Stock Forecast, Price & News

-0.15 (-1.79 %)
(As of 04/14/2021 12:00 AM ET)
Today's Range
Now: $8.24
50-Day Range
MA: $8.65
52-Week Range
Now: $8.24
Volume1.72 million shs
Average Volume22.22 million shs
Market Capitalization$191.58 million
P/E RatioN/A
Dividend YieldN/A
Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.
Second Sight Medical Products logo

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolNASDAQ:EYES
Year FoundedN/A



Sales & Book Value

Annual Sales$3.38 million
Book Value$0.47 per share


Net Income$-33,590,000.00


Market Cap$191.58 million
Next Earnings DateN/A


April 8, 2021 |
Second Sight Medical Products Looks Overvalued
April 2, 2021 |
Second Sight Medical Products (NASDAQ:EYES)
March 27, 2021 |
See More Headlines


Overall MarketRank

0.81 out of 5 stars

Medical Sector

1187th out of 2,019 stocks

Electromedical Equipment Industry

32nd out of 61 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
-0.15 (-1.79 %)
(As of 04/14/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EYES News and Ratings via Email

Sign-up to receive the latest news and ratings for EYES and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Second Sight Medical Products (NASDAQ:EYES) Frequently Asked Questions

What stocks does MarketBeat like better than Second Sight Medical Products?

Wall Street analysts have given Second Sight Medical Products a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Second Sight Medical Products wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Second Sight Medical Products?

Second Sight Medical Products saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 2,400,000 shares, a drop of 22.6% from the March 15th total of 3,100,000 shares. Based on an average trading volume of 23,710,000 shares, the short-interest ratio is presently 0.1 days. Approximately 38.2% of the company's shares are short sold.
View Second Sight Medical Products' Short Interest

How were Second Sight Medical Products' earnings last quarter?

Second Sight Medical Products, Inc. (NASDAQ:EYES) posted its quarterly earnings results on Monday, June, 29th. The medical device company reported ($0.57) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.16.
View Second Sight Medical Products' earnings history

How has Second Sight Medical Products' stock price been impacted by Coronavirus (COVID-19)?

Second Sight Medical Products' stock was trading at $3.53 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EYES stock has increased by 133.4% and is now trading at $8.24.
View which stocks have been most impacted by COVID-19

Who are Second Sight Medical Products' key executives?

Second Sight Medical Products' management team includes the following people:
  • Mr. Scott Dunbar, Acting Chief Exec. Officer
  • Gunnar Bjorg, Founder
  • Edward Jonathon Sedo, Acting Chief Accounting Officer & Principal Accounting and Financial Officer
  • Mr. Edward David Randolph, VP of Operations (Age 63)
  • Mr. Stephen D. Okland Jr., Chief Strategy & Bus. Devel. Officer (Age 57, Pay $403.75k)
  • Ms. Lisa M. Wilson, Founder & Pres of In-Site Communications and Investor Relations for Second Sight (Age 56)

What is Will McGuire's approval rating as Second Sight Medical Products' CEO?

5 employees have rated Second Sight Medical Products CEO Will McGuire on Will McGuire has an approval rating of 57% among Second Sight Medical Products' employees. This puts Will McGuire in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Second Sight Medical Products' key competitors?

What other stocks do shareholders of Second Sight Medical Products own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), Cara Therapeutics (CARA), VBI Vaccines (VBIV), Shopify (SHOP), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), (CGC), Ekso Bionics (EKSO) and OPKO Health (OPK).

When did Second Sight Medical Products IPO?

(EYES) raised $32 million in an IPO on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC acted as the underwriter for the IPO.

What is Second Sight Medical Products' stock symbol?

Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."

How do I buy shares of Second Sight Medical Products?

Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Second Sight Medical Products' stock price today?

One share of EYES stock can currently be purchased for approximately $8.24.

How much money does Second Sight Medical Products make?

Second Sight Medical Products has a market capitalization of $191.58 million and generates $3.38 million in revenue each year. The medical device company earns $-33,590,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis.

How many employees does Second Sight Medical Products have?

Second Sight Medical Products employs 12 workers across the globe.

What is Second Sight Medical Products' official website?

The official website for Second Sight Medical Products is

Where are Second Sight Medical Products' headquarters?

Second Sight Medical Products is headquartered at 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342.

How can I contact Second Sight Medical Products?

Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]

This page was last updated on 4/15/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.